摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(4-benzyloxy-phenyl)-(6-bromoquinazolin-4-yl)-amine | 179248-66-9

中文名称
——
中文别名
——
英文名称
(4-benzyloxy-phenyl)-(6-bromoquinazolin-4-yl)-amine
英文别名
(4-benzyloxy-phenyl)-(6-bromo-quinazolin-4-yl)-amine;6-bromo-N-(4-phenylmethoxyphenyl)quinazolin-4-amine
(4-benzyloxy-phenyl)-(6-bromoquinazolin-4-yl)-amine化学式
CAS
179248-66-9
化学式
C21H16BrN3O
mdl
——
分子量
406.282
InChiKey
XFTUDEYATQLWOU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    554.4±50.0 °C(Predicted)
  • 密度:
    1.467±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.6
  • 重原子数:
    26
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    47
  • 氢给体数:
    1
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Anilinoquinazaolines as protein tyrosine kianse inhibitors
    申请人:Cockerill Stuart George
    公开号:US20050143401A1
    公开(公告)日:2005-06-30
    Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
    本发明描述了杂环芳香化合物,它们的制备方法,含有它们的药物组合物,使用方法以及它们在药物中的应用。特别是,本发明涉及表现出蛋白酪氨酸激酶抑制活性的喹唑啉和吡啶嘧啶衍生物。
  • Fused heterocyclic compounds as protein tyrosine kinase inhibitors
    申请人:SmithKline Beecham Corporation
    公开号:US06391874B1
    公开(公告)日:2002-05-21
    Substituted heteroaromatic compounds of formula (I) and in particular substituted quinolines and quinazolines, are protein tyrosine kinase inhibitors. The compounds are described as are methods for their preparation, pharmaceutical compositions including such compounds and their use in medicine, for example in the treatment of cancer and psoriasis, or a salt or solvate thereof; wherein X is N or CH; Y is a group W(CH2), (CH2)W, or W, in which W is O, S(O)m wherein m is 0, 1 or 2, or NRa wherein Ra is hydrogen or a C1-8 alkyl group; R1 represents a phenyl group or a 5- or 6-membered heterocyclic ring containing 1 to 4 heteroatoms selected from N, O or S(O)m, wherein m is as defined above, with the provisos that the ring does not contain two adjacent O or S(O)m atoms and that where the ring contains only N as heteroatom(s) the ring is C-linked to the quinazoline or quinoline ring, R1 being optionally substituted by one or more R3;groups; P=0 to 3; U, R2, R3 are as defined in the application.
    代替的杂环芳烃化合物的化学式(I),特别是代替的喹啉和喹唑啉,是蛋白酪氨酸激酶抑制剂。这些化合物的制备方法被描述,包括含有这些化合物的药物组合物以及它们在医学上的用途,例如用于癌症和牛皮癣的治疗,或其盐或溶剂化合物;其中X为N或CH;Y为W(CH2)、(CH2)W或W的基团,其中W为O、S(O)m,其中m为0、1或2,或NRa,其中Ra为氢或C1-8烷基基团;R1代表苯基或含有1至4个来自N、O或S(O)m的杂原子的5-或6元杂环环,其中m如上定义,但环不含有两个相邻的O或S(O)m原子,并且当环仅含有N作为杂原子时,环与喹唑啉或喹啉环C键连接,R1可选择地被一个或多个R3基团取代;P = 0到3;U、R2、R3如申请中所定义。
  • Heterocyclic compounds
    申请人:——
    公开号:US20020147205A1
    公开(公告)日:2002-10-10
    The present invention relates to substituted heteroaromatic compounds, methods for their preparation, pharmaceutical compositions containing them and their use in medicine. Specifically, the invention relates to quinazoline derivatives useful in treating disorders mediated by protein tyrosine kinase activity, in particular erbB-2 and/or EGFR activity.
    本发明涉及替代杂环芳香化合物,其制备方法,包含它们的制药组合物以及它们在医学上的用途。具体而言,本发明涉及喹唑啉衍生物,用于治疗由蛋白酪氨酸激酶活性介导的紊乱,特别是erbB-2和/或EGFR活性。
  • HETEROCYCLIC COMPOUNDS
    申请人:CARTER Clive Malcolm
    公开号:US20070238875A1
    公开(公告)日:2007-10-11
    A process for the preparation of a compound of formula (I) comprising the steps: (a) reacting a compound of formula (II) wherein L and L′ are suitable leaving groups, with a compound of formula (III) UNH 2 (III) to prepare a compound of formula (IV) and subsequently (b) substituting the group R 1 by replacement of the leaving group L′.
    一种制备化合物(I)的方法,包括以下步骤:(a)将式为(II)的化合物与式为(III)的化合物UNH2(III)反应,其中L和L'是适当的离去基团,以制备式为(IV)的化合物;随后(b)通过替换离去基团L'来取代基团R1。
  • BICYCLIC HETEROAROMATIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS
    申请人:GlaxoSmithKline LLC
    公开号:US20150065527A1
    公开(公告)日:2015-03-05
    A pharmaceutical formulation comprising the compound of formula
    一种药物配方,其中包含化学式的化合物。
查看更多